Earnest Partners LLC boosted its position in MEDNAX Inc (NYSE:MD) by 48.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,212,691 shares of the company’s stock after acquiring an additional 718,317 shares during the quarter. MEDNAX accounts for about 1.1% of Earnest Partners LLC’s holdings, making the stock its 20th biggest holding. Earnest Partners LLC owned 2.36% of MEDNAX worth $118,246,000 at the end of the most recent reporting period.
A number of other large investors have also recently modified their holdings of MD. Fuller & Thaler Asset Management Inc. acquired a new stake in MEDNAX in the third quarter valued at approximately $103,000. Meiji Yasuda Asset Management Co Ltd. raised its holdings in MEDNAX by 45.3% during the third quarter. Meiji Yasuda Asset Management Co Ltd. now owns 5,230 shares of the company’s stock worth $226,000 after purchasing an additional 1,630 shares in the last quarter. Delta Capital Management LLC acquired a new stake in MEDNAX during the fourth quarter worth approximately $227,000. Brown Advisory Inc. acquired a new stake in MEDNAX during the fourth quarter worth approximately $231,000. Finally, YHB Investment Advisors Inc. acquired a new stake in MEDNAX during the fourth quarter worth approximately $235,000. 98.53% of the stock is currently owned by hedge funds and other institutional investors.
MEDNAX Inc (NYSE:MD) opened at $57.58 on Monday. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.60. The stock has a market cap of $5,400.75, a P/E ratio of 18.34, a PEG ratio of 1.43 and a beta of 0.26. MEDNAX Inc has a 1 year low of $40.56 and a 1 year high of $71.26.
A number of research firms have weighed in on MD. Robert W. Baird raised their price objective on shares of MEDNAX from $48.00 to $54.00 and gave the stock a “neutral” rating in a report on Friday, February 9th. Zacks Investment Research raised shares of MEDNAX from a “hold” rating to a “buy” rating and set a $60.00 price objective on the stock in a report on Tuesday, January 23rd. Mizuho set a $49.00 price objective on shares of MEDNAX and gave the stock a “hold” rating in a report on Wednesday, January 24th. Stifel Nicolaus reissued a “hold” rating and set a $56.00 price objective on shares of MEDNAX in a report on Wednesday, January 24th. Finally, JPMorgan Chase & Co. raised their price objective on shares of MEDNAX from $46.00 to $55.00 and gave the stock a “neutral” rating in a report on Monday, February 12th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and four have issued a buy rating to the stock. MEDNAX currently has a consensus rating of “Hold” and an average target price of $54.92.
In other news, insider John C. Pepia sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 12th. The shares were sold at an average price of $51.58, for a total transaction of $154,740.00. Following the transaction, the insider now directly owns 35,569 shares in the company, valued at $1,834,649.02. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 2.40% of the company’s stock.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MEDNAX Inc (NYSE:MD).
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.